Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05987124 · ClinicalTrials.gov registry record · Phase 2
Defibrotide Dose-escalation for SOS Post-HSCT
A Phase 2 study of Veno-occlusive Disease and Sinusoidal Obstruction Syndrome, sponsored by New York Medical College.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05987124 is a Phase 2 study of Veno-occlusive Disease and Sinusoidal Obstruction Syndrome that is actively recruiting participants, run by New York Medical College. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05987124, a Phase 2 study of Veno-occlusive Disease and Sinusoidal Obstruction Syndrome, is actively recruiting participants, sponsored by New York Medical College.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses of defibrotide.
Conditions Studied
Interventions
- DRUG Defibrotide
Study Locations (1)
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-03-20 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05987124
The ClinicalTrials.gov registry entry for NCT05987124 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Veno-occlusive Disease appearing as the primary indexed condition, and to 1 intervention - of which Defibrotide is the first listed.
NCT05987124 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05987124 about?
NCT05987124 is a clinical study titled "Defibrotide Dose-escalation for SOS Post-HSCT". This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)/veno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and/or lung impai...
What is the current status of trial NCT05987124?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-03-20. Estimated completion is 2027-08-01.
What conditions does trial NCT05987124 study?
This clinical trial studies the following conditions: Veno-occlusive Disease, Sinusoidal Obstruction Syndrome.
What interventions are being tested in trial NCT05987124?
The interventions under investigation include: Defibrotide (DRUG).
Who is sponsoring clinical trial NCT05987124?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05987124 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Veno-occlusive Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.